Skip to main content

Advertisement

Table 1 Clinico-pathological characteristics of patients in cohort 1 and 2 split by CCND1 amplification status

From: The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours

Variable Cohort 1 (n = 1965) P Cohort 2 (n = 340) P
Non-Amp Amp Non-Amp Amp
n (%) n (%) n (%) n (%)
1539 (78) 426 (22) 221 (65) 119 (35)
ER
 Positive 1129 (73) 377 (88) < 0.001 158 (71) 93 (78) 0.182
 Negative 410 (27) 49 (12)   63 (29) 26 (22)  
PR
 Positive 794 (52) 231 (54) 0.364 140 (63) 71 (60) 0.504
 Negative 745 (48) 195 (46)   81 (37) 48 (40)  
HER2
 Positive 190 (12) 57 (13) 0.626 40 (18) 30 (25) 0.122
 Negative 1349 (88) 369 (87)   181 (82) 89 (75)  
Elston–Ellis grade
 I 148 (10) 22 (5) 0.200* 22 (10) 9 (8) 0.400*
 II 625 (43) 142 (34)   102 (47) 47 (40)  
 III 690 (47) 252 (61)   93 (43) 62 (52)  
 Missing cases = 86     Missing cases = 5   
LN status
 Positive 748 (49) 188 (44) 0.114 116 (52) 81 (68) 0.005
 Negative 791 (51) 238 (56)   105 (48) 38 (32)  
Tumour size
 < 20 mm 497 (33) 120 (28) 0.108 101 (47) 51 (43) 0.492
 ≥ 20 mm 1026 (67) 303 (72)   115 (53) 68 (57)  
 Missing cases = 19     Missing cases = 5   
Age
 ≤ 45 208 (14) 41 (10) 0.006 11 (12) 7 (10) 0.825
 45–55 312 (20) 69 (16)   78 (83) 53 (82)  
 ≥ 55 1019 (66) 316 (74)   5 (5) 5 (8)  
     Missing cases = 181   
IHC subgroups
 ER+/LN−/HER2− 581 (38) 190 (45) < 0.001 64 (29) 26 (23) 0.142
 ER+/LN+/HER2− 482 (31) 145 (34)   75 (34) 47 (39)  
 HER2+ 190 (12) 57 (13)   40 (18) 30 (25)  
 TN (ER−/PR−/HER2−) 286 (19) 34 (8)   42 (19) 16 (13)  
PAM50
 Luminal A 602 (39) 116 (27) < 0.001 77 (35) 38 (32) 0.051
 Luminal B 291 (19) 197 (46)   36 (16) 32 (27)  
 HER2-enriched 184 (12) 54 (14)   30 (14) 20 (17)  
 Basal-like 289 (19) 31 (7)   55 (25) 24 (20)  
 Normal-like 168 (11) 27 (6)   23 (10) 5 (4)  
 Missing cases = 6       
Treatments
 Endocrine therapy 773 (50) 249 (58) < 0.001 59 (27) 33 (27) 0.950
 Chemotherapy 196 (13) 25 (6)   60 (27) 30 (25)  
 Both 148 (10) 41 (10)   99 (45) 55 (47)  
 None 422 (27) 111 (26)   3 (1) 1 (1)  
  1. Correlations were calculated using X2 test unless otherwise specified
  2. ER oestrogen receptor alpha, PR progesterone receptor, HER2 human epidermal growth factor 2 receptor, TN triple negative (ER−/PR−/HER2−), LN lymph node status, Amp/non-Amp CCND1 amplified/non-amplified, Both patients sequentially received chemotherapy and endocrine therapy
  3. * = Wilcoxon/Mann–Whitney